Columbia Laboratories, Inc. (CBRX)

[Degreed]

BPAX was approved and it was a easy approval. CORT was either or lol.

DSCO will be approved I'm in that been in adding on dips. When you have negative review from the Advisory board it's a hard sell. Less then 30% of the time does the FDA go against what the board recommends.

Add to that there is already a 4% Progresterone bioadhesive on the market. Now magically you up that to 8% and it's being called a new drug with a new market?

I just don't see it being approved, but place your bets should be a great gap if it is!! With minimal downside if it isn't maybe high .60's low 70's.